We are pleased to announce details of a Special Edition OBN BioTuesday event, providing an overview and update from the industry on: ‘What’s happening in Cancer?’
Our high-level speakers will give an update on the latest innovative technologies and breakthroughs in cancer therapies by scientists and R&D companies in the Oxford area. They will also provide an overview of how the latest drug discoveries are being funded, focusing on the move towards collaboration between academia and big pharma to help accelerate the discovery process and introduce ground-breaking treatments into a clinical setting far sooner than ever before.
The event is kindly co-hosted by Ipsen and Immunocore and is being held at the Ipsen Bioinnovation on Milton Park, Oxford, which is the UK R&D Centre for Ipsen on Tuesday 21st November.
About our hosts:
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumours, renal cell carcinoma and pancreatic cancer.
Immunocore is the world’s leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, through its pioneering soluble TCR technology platform. The scientific expertise at Immunocore spans the entire process of drug development. From the discovery and validation of suitable disease targets, through to the design and engineering of immune-activating TCR-based reagents, and preclinical and clinical assessment.
17:30 Registration and networking
18:00 Welcome and introductions from Dr John Harris, CEO of OBN (UK), Dr John Chaddock, Vice President Neurology & Site Head at Ipsen Bioinnovation and Philip Campbell, Commercial Director.
18:10 Sarah Blagden, Associate Professor of Experimental Cancer Medicine, University of Oxford Department of Oncology - Sarah has been Associate Professor of Experimental Cancer Therapeutics in the Department of Oncology since 2015. Following medical training and subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, she was awarded a CRUK Junior Clinician Scientist PhD fellowship in 1999 at Cambridge University and held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.
Sarah will provide an update on the latest clinical trials and scientific discoveries being spun out from the Oxford area.
18.25 David Rich, Medical Development Director (Global) Endocrinology/Oncology, Ipsen – David joined Ipsen in April 2015. As a Medical Development Director, David leads the strategy & development of a molecule from the first studies in man through to when it becomes available to patients. The role has many aspects including the design of the numerous clinical trials and discussion with both health care professionals, patients and regulatory agencies.
18.40 Dr Eliot Forster, CEO of Immunocore - Eliot joined Immunocore as Chief Executive Officer in January 2015. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and will share an update on the latest developments and collaborations connected with their T-cell receptor cancer treatments
18.55 Peter Nolan, Chief Business Officer of Oxford Biomedica - Peter Nolan was appointed to Oxford BioMedica's Board in May 2002, having been a senior member of the Company since its foundation. He has broad experience and knowledge of the biotechnology sector
19.10 Showcase Presentations – 3 x 5-minute showcase presentation opportunities for Oxford based early stage companies involved in cancer research
Showcase one: Nicholas La Thangue, Chief Scientific Officer,
Showcase two: Dara Henry, VP of Operations & Business Development,
Showcase three: Colin Stubberfield, Principal, Scientist,
19:40 Panel discussion and Q&A, chaired by John Chaddock
20.00 Networking over drinks and canapés
21:30 Evening close
Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon, OX14 4RY
Tickets: *Sold out*
OBN Member – first ticket complimentary, additional ticket £25+VAT
Non Members - £50+VAT